The article discusses the evolution of anti-vascular endothelial growth factor (VEGF) therapy in treating patient with age-related macular degeneration (AMD), retinal vein occlusions and diabetic macular edema. Topics mention including challenges in bringing the efficacy which are demonstrated in clinical trials, development of Port Delivery System (PDS) by Roche and targeting of platelet-derived growth factor (PDGF).
- RETINAL degeneration treatment
- VASCULAR endothelial growth factors
- EYE diseases
- RETINAL vein occlusion
- PLATELET-derived growth factor